NVCN: Tiara Featured in Live Case 11th Annual TVT 2018
Jun 21, 2018 23:48:02 GMT
stcks and c2crusher like this
Post by icemandios on Jun 21, 2018 23:48:02 GMT
Tiara™ Featured in Live Case at 11th Annual TVT 2018
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
NASDAQ, TSX: NVCN
VANCOUVER, June 21, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2018"). TVT 2018 is part of The Structural Heart Disease Summit held June 20-23 in Chicago, Illinois.
In a live case broadcast to the main arena of the conference, Dr. Anson Cheung, and Dr. John G. Webb of St. Paul's Hospital (Vancouver, Canada) successfully implanted a 40mm Tiara transcatheter mitral valve in a patient suffering from severe mitral regurgitation.
Dr Anson Cheung commented following the case, "This patient suffered from severe mitral regurgitation and a number of co-morbidities which made him a very poor candidate for surgery. The Heart Team weighed in on all available treatment options and determined the Tiara device was the best option for this patient. The Tiara case was very straight-forward, with an implant time of under 20 minutes, with no procedural complications.
Following the Tiara implant the patient's mitral regurgitation was completely resolved, with a 1mmHg gradient and no paravalvular leak. The patient is recovering well at this time."
"This live case broadcast reinforced Tiara's potential as a promising treatment option for patients who are not suitable for open-heart surgical valve replacement," commented Fred Colen, Neovasc's President and Chief Executive Officer. "Attending physicians were able to see first-hand the simplicity of the minimally invasive, transapical transcatheter approach and resulting complete elimination of the patient's MR. We look forward to continuing to expand our Tiara clinical program and ultimately the adoption of Tiara for routine use in these patients once regulatory approvals are obtained."
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
